<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678688</url>
  </required_header>
  <id_info>
    <org_study_id>323-201-00003</org_study_id>
    <secondary_id>OPP1178898</secondary_id>
    <nct_id>NCT03678688</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</brief_title>
  <official_title>A Phase 1/2, Active-controlled, Randomized, Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Oral Doses of OPC-167832 Tablets in Subjects With Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of&#xD;
      multiple oral doses of OPC-167832 in subjects with uncomplicated, smear-positive,&#xD;
      drug-susceptible pulmonary tuberculosis (TB).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This will be a multiple-dose trial of OPC-167832 with 2 stages.&#xD;
Stage 1 is a multiple ascending dose trial planned to be conducted in 4 sequential cohorts of 18 participants each. There will be 2 arms (OPC-167832, RHEZ) in each cohort.&#xD;
Stage 2 will be a parallel group comparison of 4 treatment regimens: 1) OPC-167832 plus Delamanid 2) OPC-167832 plus Bedaquiline 3) OPC-167832 plus Delamanid plus Bedaquiline 4) RHEZ.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TB bacterial load in sputum</measure>
    <time_frame>baseline to Day 14</time_frame>
    <description>Stage 1:&#xD;
The change in TB bacterial load in sputum as a measure of early bactericidal activity (EBA) and measured by colony-forming unit (CFU) counts on solid media cultures. The EBA will be measured as the slope of the change in log-CFU from baseline (ie, the mean of the values from Day -2 and Day -1) to Day 14.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma drug levels of OPC-167832 and/or delamanid and/or Bedaquiline (BDQ) at specified pre-dose and post-dose time points</measure>
    <time_frame>up to Day 14-20</time_frame>
    <description>Stage 1:&#xD;
PK parameters will be determined for plasma OPC-167832&#xD;
Stage 2:&#xD;
PK parameters will be determined for plasma OPC-167832, Delamanid, and BDQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to follow-up visit, an average of 28 days</time_frame>
    <description>Stage 1 and Stage 2: The incidence of AEs and the incidence of abnormal laboratory findings in clinical laboratory tests (serum chemistry, hematology, urinalysis, and coagulation), physical examinations, vital signs, and electrocardiograms will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in sputum lipoarabinomannan (LAM) concentration and time to detection (TTD) in the Mycobacteria Growth Indicator Tube® (MGIT) system</measure>
    <time_frame>baseline to Day 14</time_frame>
    <description>Stage 1:&#xD;
The slope of the change in log-LAM values of OPC-167832 and the change in TTD in the Mycobacteria Growth Indicator Tube® (MGIT) system.&#xD;
Stage 2:&#xD;
The change in TB bacterial load in sputum as a measure of early bactericidal activity (EBA) and measured by colony-forming unit (CFU) counts on solid media cultures. The EBA will be measured as the slope of the change in log-CFU from baseline (ie, the mean of the values from Day -2 and Day -1) to Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of rifampin and isoniazid at specified post-dose time points</measure>
    <time_frame>Day 14</time_frame>
    <description>Stage 1 and Stage 2 Plasma concentrations of rifampin and isoniazid at 2 and 6 hours post-dose will be determined for compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of DM-6705 (metabolite of delamanid) and M2 (metabolite of BDQ) at specified pre-dose and post-dose time points</measure>
    <time_frame>Day 1, 2, and 12-20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of QT interval and plasma concentrations of OPC-167832 and/or delamanid and/or Bedaquiline</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Stage 1 and 2&#xD;
The maximum effect and EC80 for OPC-167832, regardless of dose level, will be determined from an exposure-response analysis of the results from the Otsuka TB ELISA LAM.&#xD;
The relationship between QT interval and plasma concentrations of OPC-167832 (stage&#xD;
1) and OPC-167832 when administered with delamanid and/or BDQ (stage 2) will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs of OPC-167832 with delamanid and or Bedaquiline</measure>
    <time_frame>Up to follow-up visit, an average of 28 days</time_frame>
    <description>Stage 1 and 2:&#xD;
Incidence of AEs and the incidence of abnormal laboratory findings in clinical laboratory tests (serum chemistry, hematology, urinalysis, and coagulation), physical examinations, vital signs, and electrocardiograms of OPC-167832 when administered with delamanid and/or BDQ (data derived from stage 2) will be compared with the administration of OPC-167832 alone (data derived from stage 1).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Pulmonary TB</condition>
  <arm_group>
    <arm_group_label>Stage 1 and Stage 2: RHEZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: OPC-167832/Delamanid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: OPC-167832/Bedaquiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: OPC-167832/Delamanid/Bedaquiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg OPC-167832</intervention_name>
    <description>Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.</description>
    <arm_group_label>Stage 1 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg OPC-167832</intervention_name>
    <description>Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.</description>
    <arm_group_label>Stage 1 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mg OPC-167832</intervention_name>
    <description>Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.</description>
    <arm_group_label>Stage 1 Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg OPC-167832</intervention_name>
    <description>Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.</description>
    <arm_group_label>Stage 1 Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHEZ</intervention_name>
    <description>RHEZ will be used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants will receive a single-dose from Day 1 through Day 20. The total number of tablets per day will be based on the pretreatment body weight:&#xD;
Participants weighing 30 to 37 kg will receive 2 tablets per day&#xD;
Participants weighing 38 to 54 kg will receive 3 tablets per day&#xD;
Participants weighing 55 to 70 kg will receive 4 tablets per day&#xD;
Participants weighing &gt; 70 kg will receive 5 tablets per day</description>
    <arm_group_label>Stage 1 and Stage 2: RHEZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg OPC-167832 plus 300 mg delamanid</intervention_name>
    <description>Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.</description>
    <arm_group_label>Stage 2: OPC-167832/Delamanid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg OPC-167832 plus 400 mg Bedaquiline (BDQ)</intervention_name>
    <description>Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Subjects will receive a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ will be 400 mg QD for Days 3 to 14.</description>
    <arm_group_label>Stage 2: OPC-167832/Bedaquiline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg OPC-167832 plus 300 mg delamanid plus 400 mg Bedaquiline (BDQ)</intervention_name>
    <description>Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Subjects will receive a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ will be 400 mg QD for Days 3 to 14.</description>
    <arm_group_label>Stage 2: OPC-167832/Delamanid/Bedaquiline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written, informed consent prior to initiation of any trial-related&#xD;
             procedures, and able, in the opinion of the investigator, to comply with all the&#xD;
             requirements of the trial.&#xD;
&#xD;
          -  Male or female participants between 18 and 64 years of age (inclusive) at the&#xD;
             screening visit.&#xD;
&#xD;
          -  Body mass index ≥ 16.0 and ≤ 32.0 kg/m^2 (inclusive) at the screening visit.&#xD;
&#xD;
          -  Newly diagnosed, uncomplicated, drug-susceptible pulmonary TB.&#xD;
&#xD;
          -  Microscopy performed on a sputum smear at screening indicates presence of acid-fast&#xD;
             bacilli (at least 1+).&#xD;
&#xD;
          -  Able to produce an adequate volume of sputum (approximately 10 mL or more estimated&#xD;
             overnight production).&#xD;
&#xD;
          -  Female participants of childbearing potential must agree to use 2 different approved&#xD;
             methods of birth control or remain abstinent throughout the participation in the trial&#xD;
             and for 12 weeks after the last dose of trial treatment (IMP or RHEZ).&#xD;
&#xD;
          -  Male participants must agree to use 2 different approved methods of birth control or&#xD;
             remain abstinent throughout the participation in the trial and for 12 weeks after the&#xD;
             last dose of trial treatment (IMP or RHEZ).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants are known or suspected of having resistance to rifampicin, isoniazid,&#xD;
             ethambutol, or pyrazinamide using any combination of Xpert MTB/RIF, line probe assay,&#xD;
             culture, and/or epidemiologic history at screening.&#xD;
&#xD;
          -  Poor general condition where no delay in treatment can be tolerated or where immediate&#xD;
             hospital admission is warranted.&#xD;
&#xD;
          -  Evidence of clinically significant metabolic (including ongoing or current&#xD;
             hypokalemia), gastrointestinal, neurological, psychiatric, endocrine or liver (e.g.,&#xD;
             hepatitis B and C) disease; malignancy; or other abnormalities (other than the&#xD;
             indication being studied).&#xD;
&#xD;
          -  History of or current clinically relevant cardiovascular disorder such as heart&#xD;
             failure, coronary heart disease, hypertension, arrhythmia or symptom strongly&#xD;
             suggestive of such a problem (for example, syncope or palpitations), tachyarrhythmia&#xD;
             or status after myocardial infarction.&#xD;
&#xD;
          -  Known bleeding disorders or family history of bleeding disorders.&#xD;
&#xD;
          -  Any diseases or conditions in which the use of delamanid, rifampicin, isoniazid,&#xD;
             pyrazinamide, ethambutol, or Bedaquiline is contraindicated.&#xD;
&#xD;
          -  Any prior treatment for M. tuberculosis within the past 3 years.&#xD;
&#xD;
          -  Any treatment with a drug active against M. tuberculosis (e.g., quinolones) within the&#xD;
             3 months prior to screening.&#xD;
&#xD;
          -  Clinical evidence of severe extrapulmonary TB (e.g., miliary TB, abdominal TB,&#xD;
             urogenital TB, osteoarthritic TB, TB meningitis).&#xD;
&#xD;
          -  Evidence of pulmonary silicosis, lung fibrosis, or other lung condition considered as&#xD;
             severe by the investigator (other than TB). In particular any underlying condition&#xD;
             that could interfere with the assessment of x-ray images, sputum collection, or&#xD;
             interpretation of sputum findings, or otherwise compromise the subject's participation&#xD;
             in the trial.&#xD;
&#xD;
          -  Any renal impairment characterized by serum creatinine clearance of &lt;60 mL/min, or&#xD;
             hepatic impairment characterized by alanine transaminase, aspartate transaminase, or&#xD;
             total bilirubin &gt;1.5 x upper limit of normal of the clinical laboratory reference&#xD;
             range at screening.&#xD;
&#xD;
          -  For Stage 1, participants who are HIV positive are excluded. For Stage 2, participants&#xD;
             with HIV co-infection who are on antiretroviral drugs during screening or with CD4&#xD;
             cell count &lt;500/mm^3 are excluded.&#xD;
&#xD;
          -  Changes in the ECG such as QTcF &gt;450 msec, atrioventricular block II or III,&#xD;
             bi-fasicular block, at screening or current history of clinically significant&#xD;
             ventricular arrhythmias. Other ECG changes if considered clinically significant by the&#xD;
             investigator.&#xD;
&#xD;
          -  Participants receiving any of the prohibited medications within the specified periods&#xD;
             or who would be likely to require prohibited concomitant therapy during the trial.&#xD;
&#xD;
          -  Female participants who are breast-feeding or who have a positive pregnancy test&#xD;
             result prior to receiving the first dose of IMP or RHEZ on Day 1.&#xD;
&#xD;
          -  History of significant drug and/or alcohol abuse within 2 years prior to screening.&#xD;
&#xD;
          -  History of or current hepatitis or carriers of HBsAg and/or anti-HCV.&#xD;
&#xD;
          -  Positive urine or blood alcohol test and/or urine drug screen for substance abuse at&#xD;
             screening (not including cannabinoids).&#xD;
&#xD;
          -  History of having taken an investigational drug within 30 days preceding trial entry&#xD;
             (ie, prior to screening).&#xD;
&#xD;
          -  A history of difficulty in donating blood.&#xD;
&#xD;
          -  Donation of blood or plasma within 30 days prior to dosing.&#xD;
&#xD;
          -  Consumption of alcohol and/or grapefruit, grapefruit juice, Seville oranges, or&#xD;
             Seville orange juice and related products within 72 hours prior to the first dose of&#xD;
             IMP or RHEZ on Day 1.&#xD;
&#xD;
          -  History of serious mental disorders that, in the opinion of the investigator, would&#xD;
             exclude the subject from participating in this trial.&#xD;
&#xD;
          -  Any known prior exposure to OPC-167832, delamanid or Bedaquiline.&#xD;
&#xD;
          -  Participants with significant medical comorbidities that in the opinion of the&#xD;
             investigator, should not participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique R de Jager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TASK Clinical Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Rodney Dawson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town (Pty) Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Development</last_name>
    <phone>609 524 6788</phone>
    <email>mailto:clinicaltransparency@otsuka-us.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cape Town (Pty) Ltd.</name>
      <address>
        <city>Cape Town</city>
        <state>Mowbray</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Rodney Dawson, MD</last_name>
      <phone>+27(0) 21 406 6850</phone>
      <email>rodney.dawson@uct.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Satellite Site: Task at Brooklyn Chest Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Eriksson</last_name>
      <phone>+27 21 5102207</phone>
      <email>michelle@task.org.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TASK Clinical Research Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique R de Jager, MD</last_name>
      <phone>+27(0) 21 917 1044</phone>
      <email>dr.veronique@task.org.za</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bedaquiline</mesh_term>
    <mesh_term>Diarylquinolines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

